Capital International Ltd. CA Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Capital International Ltd. CA lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) by 177.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,619 shares of the medical device company’s stock after purchasing an additional 2,957 shares during the quarter. Capital International Ltd. CA’s holdings in DexCom were worth $2,363,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of DexCom during the fourth quarter worth about $26,000. Riverview Trust Co bought a new stake in DexCom in the 1st quarter worth approximately $25,000. Whittier Trust Co. of Nevada Inc. lifted its position in DexCom by 85.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 74 shares of the medical device company’s stock worth $38,000 after buying an additional 34 shares during the last quarter. Bivin & Associates Inc. lifted its position in DexCom by 125.0% in the 1st quarter. Bivin & Associates Inc. now owns 90 shares of the medical device company’s stock worth $46,000 after buying an additional 50 shares during the last quarter. Finally, American National Bank lifted its position in DexCom by 33.8% in the 1st quarter. American National Bank now owns 91 shares of the medical device company’s stock worth $47,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Insider Buying and Selling

In other news, Director Steven Robert Pacelli sold 1,000 shares of the stock in a transaction on Monday, July 25th. The stock was sold at an average price of $83.07, for a total value of $83,070.00. Following the sale, the director now directly owns 138,700 shares of the company’s stock, valued at $11,521,809. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 3,000 shares of company stock valued at $239,830 over the last ninety days. Company insiders own 0.41% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent research reports. Piper Sandler dropped their target price on DexCom from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, July 29th. Citigroup dropped their target price on DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. Oppenheimer lowered their price objective on DexCom from $131.00 to $105.00 in a research report on Friday, July 29th. Sanford C. Bernstein began coverage on DexCom in a research report on Friday, July 15th. They issued an “outperform” rating and a $105.00 price objective for the company. Finally, Wells Fargo & Company lowered their price objective on DexCom from $144.00 to $102.00 in a research report on Friday, July 29th. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $115.23.

DexCom Price Performance

Shares of DXCM stock opened at $90.57 on Thursday. The stock has a market cap of $35.56 billion, a price-to-earnings ratio of 188.69, a PEG ratio of 3.75 and a beta of 1.03. The business’s fifty day moving average is $85.19 and its 200 day moving average is $92.22. DexCom, Inc. has a twelve month low of $66.89 and a twelve month high of $164.86. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.87.

DexCom (NASDAQ:DXCMGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million during the quarter, compared to analysts’ expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. DexCom’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 earnings per share. Research analysts expect that DexCom, Inc. will post 0.79 EPS for the current fiscal year.

About DexCom

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.